Pelayo and zebrafish helping in rare diseases research

PlayPLAY VIDEO

 
 
 
42.256 out of 30.000 euros

42.256 euros raised
Thanks to all!

FacebookTwitterWhatsappMail

Precipita in figures

12.910people
107projects
1.306.420euros

Congenital Disorders of Glycolysation (CDG) are severe and very rare diseases with a prevalence between 1/50.000 and 1/100.000

The project
Who is behind

Congenital Disorders of Glycosylation (CDG) are a family of serious rare diseases, with a high complexity due to the variety of affected tissues and organs. They generally involve the central nervous system, the musculoskeletal, immune, digestive and endocrine systems, and coagulation. More than 150 different diseases are known within the CDG syndrome, which can show a variety of phenotypes (set of observable features in an organism). Approximately 170 patients have been registered in Spain, but most probably the real figure is much higher. For rare diseases, each patient is unique and requires a personalized treatment.

One “ultra-rare” variant, from which only 18 cases are described world-wide, is associated to a recessive mutation on gen RFT1. The majority of patients with this mutation demise prematurely or carry severe sympthoms such as psycomotor problems, epilepsy, hearing loss and digestive disorders.

One of the major constraints in the pursuit of the genes responsible for these rare diseases is the functional check, meaning the confirmation that certain changes lead to a certain disease. In the meanwhile, animal models are an useful tool for determining if one variant affects some process or functions related to a disease. Models are also an excellent tool for investigating the mechanism that triggers the disease, and for exploring possible treatments.

Zebrafish (Danio rerio) has proven to be essential for biomedical investigation as a model organism since, despite seemingly being too phylogenetically different from humans, there is a substantial homology with the human genome. Up to 85% of the genes that can induce diseases in humans are preserved in the zebrafish. Also, developing zebrafish models for studying genetic diseases is relatively easy. When the mutation associated to a certain disease is identified, it is possible to replicate it in the zebrafish, observe the associated symptoms, and determine the affected organs and systems through microscopic and molecular studies.

What is our goal?

Provided this, the main goal of our project is to develop, through CRISPR-Cas9 genetical edition technology, a zebrafish model useful for the study of “ultra-rare” diseases with extremely limited number of patients, for which the capability of a mutation to induce a disease needs confirmation. For such, a CDG subtype associated to a mutation in the RFT1 gene. From this point, a model will be available for studying the potential triggering factors, histologic, metabolic or physiological changes, and for testing specific treatments.

Only one patient with this mutation is known in Spain: Pelayo, a small two-year old superheroe who fights for carrying on and hopes for a small genetically modified fish to bring light to this disease and contribute to the pursuit of a treatment for affected children. This is not science-fiction! Several rare diseases have found a cure through similar strategies.

Abaout Precipita
About us
FAQs
Contact
Contact us
C/Pintor Murillo, 15
28100 Alcobendas (Madrid) - España
T.+(00 34) 91 425 09 09
info@precipita.es
AENOR
A project from :Logo Ministerio
FECYT 2020. All right reserved
Legal terms | Privacy policy | Cookies policy
Powered by StockCrowd  Powered by StockCrowd
Cookies
Información que debes conocer
Este sitio web utiliza cookies, para conocer nuestra política de cookies haga click aquí. Si estás de acuerdo con nuestra política de cookies haga click en el botón continuar.